Sreenivasan (Sreeni) Narayanan

EarliTec Diagnostics is making earlier identification and treatment for autism and related early childhood vulnerabilities accessible to children everywhere. EarliTecs flagship product, EarliPoint™, is FDA authorized to diagnose and assess autism in children ages 16-30 months old and is available now.

We are pioneers in surgical navigation and precision healthcare, empowering physicians with safe, real-time, imaging solutions that improve outcomes, lower costs, and reduce radiation exposure for both patients and caregivers in minimally invasive endovascular procedures. Delivering on our commitment to improve quality of life by changing the way healthcare is delivered, our multidisciplinary team of scientists, clinicians, engineers, and software architects has developed the Intra-Operative Positioning System (IOPS™). This mobile and affordable GPS-like 3D vascular navigation system allows for greater surgical precision and control than ever before, improving device placement accuracy, simplifying complex procedures, and potentially decreasing endoleaks and costly secondary interventions. Millions of vascular procedures are performed each year with minimally invasive, endovascular procedures frequently preferred over open surgical repair. Currently, to navigate within vessels physicians rely on x-ray fluoroscopy. This technology has several critical limitations, including lack of soft tissue visualization and exposure to harmful ionizing radiation. IOPS™, which fits directly into existing workflows and operating rooms, eliminates this excessive radiation exposure by creating manipulable 3D models of the relevant anatomy. These intelligent models are created from existing imaging that is already part of the standard of care. Centerline Biomedical, Inc. was founded in 2014 as a spinoff of the Cleveland Clinic to commercialize our innovative vascular navigation technology. With a research, development, and design history rooted in the Clinic’s world-class Lerner Research Institute’s Heart and Vascular Institute, the IOPS™ platform can be further used for predictive modeling, clinical decision support, global healthcare analytics and the education and training of future surgeons and interventionists. See the IOPS™ technology in action: https://youtu.be/U8RL3_UNP8Q

EarliTec Diagnostics is making earlier identification and treatment for autism and related early childhood vulnerabilities accessible to children everywhere. EarliTecs flagship product, EarliPoint™, is FDA authorized to diagnose and assess autism in children ages 16-30 months old and is available now.

We strive to make a meaningful impact on medical practices around the world. Our team has decades of experience in healthcare, helping to build the bridge between technology and patient care. We implement tailored strategies that lead to an enhanced healthcare experience for your team and your patients.

We are pioneers in surgical navigation and precision healthcare, empowering physicians with safe, real-time, imaging solutions that improve outcomes, lower costs, and reduce radiation exposure for both patients and caregivers in minimally invasive endovascular procedures. Delivering on our commitment to improve quality of life by changing the way healthcare is delivered, our multidisciplinary team of scientists, clinicians, engineers, and software architects has developed the Intra-Operative Positioning System (IOPS™). This mobile and affordable GPS-like 3D vascular navigation system allows for greater surgical precision and control than ever before, improving device placement accuracy, simplifying complex procedures, and potentially decreasing endoleaks and costly secondary interventions. Millions of vascular procedures are performed each year with minimally invasive, endovascular procedures frequently preferred over open surgical repair. Currently, to navigate within vessels physicians rely on x-ray fluoroscopy. This technology has several critical limitations, including lack of soft tissue visualization and exposure to harmful ionizing radiation. IOPS™, which fits directly into existing workflows and operating rooms, eliminates this excessive radiation exposure by creating manipulable 3D models of the relevant anatomy. These intelligent models are created from existing imaging that is already part of the standard of care. Centerline Biomedical, Inc. was founded in 2014 as a spinoff of the Cleveland Clinic to commercialize our innovative vascular navigation technology. With a research, development, and design history rooted in the Clinic’s world-class Lerner Research Institute’s Heart and Vascular Institute, the IOPS™ platform can be further used for predictive modeling, clinical decision support, global healthcare analytics and the education and training of future surgeons and interventionists. See the IOPS™ technology in action: https://youtu.be/U8RL3_UNP8Q

Startup focused on developing "ALWINE"​, an ecosystem of ALWINE SENSOR(s) and ALWINE APP (cloud based ICDA platform) , for lowering the barriers to medication adherence.

Siemens AG (Berlin and Munich) is a leading technology company focused on industry, infrastructure, mobility, and healthcare. The company’s purpose is to create technology to transform the everyday, for everyone. By combining the real and the digital worlds, Siemens empowers customers to accelerate their digital and sustainability transformations, making factories more efficient, cities more livable, and transportation more sustainable. A leader in industrial AI, Siemens leverages its deep domain know-how to apply AI – including generative AI – to real-world applications, making AI accessible and impactful for customers across diverse industries. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare. For everyone. Everywhere. Sustainably. In fiscal 2025, which ended on September 30, 2025, the Siemens Group generated revenue of €78.9 billion and net income of €10.4 billion. As of September 30, 2025, the company employed around 318,000 people worldwide on the basis of continuing operations.